January 2024 Liposphere – Enabling smooth articulation of joints







Disclaimer Liposphere



This document (the "Memorandum") has been prepared by Liposphere Ltd. ("Company"). It is being provided to a limited number of recipients (each a "Recipient"), for the sole purpose of evaluating their interest in the potential equity raising of the Company ("the Transaction"). Investing in biotechnology ventures such as Liposphere Ltd. is risky and may result in the loss of all or a portion of the invested capital.

This Memorandum does not purport to be all-inclusive or to contain all information that a prospective investor may desire in investigating the Transaction. The Memorandum has been prepared for informational purposes relating to this Transaction only.

The Company does not make any express or implied representations or warranty as to the accuracy or completeness of the information contained in, or for any omissions from, the Memorandum or any additional evaluation material made available in connection with any further investigation of the Transaction. In addition, the Company expressly disclaims any and all liability which may be based on such information, errors therein or omissions therefrom.

No representation or warranty is given, and no liability is accepted, as to the achievement or reasonableness of any future projections, forecasts, estimates, or statements as to prospects or future returns contained, or referred to, in this Memorandum and nothing in this Memorandum is or should be relied on as a promise or representation as to the future.

Only those particular representation and warranties, if any, which may be made to an investor in a definitive written agreement regarding the Transaction, when, as and if executed, and subject to such limitations and restrictions as may be specified therein, will have any legal effect. In furnishing this Memorandum the company does not undertake any obligation to provide the recipient with access to any additional information or to update the Memorandum or any additional information which may be provided to the Recipient.

Neither the recipient of this Memorandum by any person nor any information contained herein or supplied herewith or subsequently communicated to any person in connection with the Transaction constitutes or is to be taken as constituting the giving of investment advice to any such person. It is the responsibility of the recipient, together with his legal, tax, financial, accounting advisers and other experts where appropriate, to carry out its own research and analysis and to form its opinions on the Transaction without relying exclusively on the information which was provided to the recipient.

The company reserves the right to negotiate with one or more prospective investors at any time and to enter into a definitive agreement for the Transaction, without prior notice to the other prospective investors. The Company reserves the right to exclude at any time from the Transaction process any prospective investors without assigning any reason therefore. The Company reserves the right to terminate, at any time, solicitations of indications of interest in relation to the Transaction. The Company reserves the right to amend, vary or terminate, at any time, any procedures relating to the Transaction process without assigning any reason therefore.

This Memorandum and the information contained herein are strictly confidential. Please contact the Company prior to forwarding this material.



AqueousJoint The first knee joint boundary lubricant for Osteoarthritis

- 500 million people globally suffer from Osteoarthritis, which causes daily pain and loss of mobility, and that number is growing 8% a year as obesity increases and the world's population lives longer.
- There are currently <u>no effective non-surgical treatments</u> that can consistently relieve the symptoms of OA on an ongoing basis.
- Liposphere has developed a unique, IP-protected, knee joint injectable biolubricant called **AqueousJoint** that forms a protective coating on the cartilage surface of the joint to provide safe, long-term pain relief and increased mobility while mechanically improving lubrication between the articulating surfaces.
- Liposphere is currently raising USD 25m Series B to accelerate market access in Europe.
- Further use cases of the technology (established in collaboration with industrial market leaders): cosmetic moisturizer; Iubricious coating for contact lenses.



About us Liposphere Company

04

"We have developed a unique IP-protected platform technology of unmatched biolubricants for orthopedic applications."






Pinpointing the problem Osteoarthritis (OA)




- > Progressive breakdown/loss of cartilage
- > Pain and limitation of active lifestyle
- // Current treatment solutions:
 partially beneficial and time-limited



Over 500M people globally suffer from Osteoarthritis.



Osteoarthritis Current solutions and market






AqueousJoint Our Solution

"A revolutionary, injectable knee joint articulation compound

that *coats and protects cartilage to reduce wear-induced pain.*"




Hydration Lubrication Mechanism enabling smooth articulation by mechanically reducing friction and wear.

U.Raviv, J. Klein, Science, 297, 5586 (2002)



AqueousJoint technology

Liposphere's joint articulation compound





Key metrics Accomplished Milestones

Preclinical/clinical milestones

- ✓ ISO 13485:2016 certification
- ✓In-house manufacturing of clinical batches
- ✓ Preclinical efficacy and biocompatibility
- ✓ First-In-Human clinical safety trial completed:
- Single intra-articular injection in moderate knee OA (~ 90% KL grade 3)
- Safety demonstrated, efficacy shown
- Clinical efficacy trial vs placebo ongoing
 Randomized, double-blinded, multi-centre; in Israel

Strategic and business milestones

- ✓ Established IP license (TTO Weizmann, Yeda)
- ✓ Filed own patents
- ✓ Raised private and governmental funding
- ✓ Finalist MassChallenge, Spinoff Prize, MIT IDEA²
- ✓ ATiO Best Early-Stage Company Award
- ✓ Winner AO development incubator
- ✓ AO Foundation Davos as 'strategic' partner









רשות החדשנות
 Israel Innovation
 Authority







Performance Why **Aqueous**Joint?



// Demonstrated significant pain reduction in an OA animal model.

- Surgically induced cartilage defect model in rats (DMM model)
- AqueousJoint injections have shown superior and long-lasting pain reduction
- compared to top HA injections (weight bearing assessment).




// Proven safety and efficacy in human clinical trials

- Single local knee joint injection of AqueousJoint demonstrated safety (52 patients so far)
- > No adverse material-related side effects reported.
- > Significant pain reduction shown over study period of 6 months in FiH trial.
- Ongoing randomized, multi-centered, double-blinded efficacy trial:
- > Significant pain reduction from baseline for AJ at 12 weeks timepoint.
- > Superiority vs placebo shown at 12 weeks.



Wear reduction demonstration ex-vivo



* The commercial lubricant is Bovine Calf Serum, the standard for prosthetic implant approval wear testings.



An outlook Next steps **Aqueous**Joint

CE mark approval Q3 2025

11

Efficacy Clinical trial initiation (vs HA) Europe Q2 2024

Completion Clinical Efficacy (vs Placebo) Israel Q1/2 2024

Series B Financing Round (\$ 25m) Q1 2024



Series B Accelerated timetable and de-risking since Series A

12



Series B raise of USD 25m to accelerate market access in Europe.




Unlocking potential beyond Series B

Four key milestones to unlock upside valuations



Sign with a major distribution partner to disrupt and dominate EU market




AJ efficacy vs HA

2

4

Plan, construct and operationalize a large manufacturing facility



Achieve a significant price premium in the market (based on efficacy)



13



Valuation upside

14

Investor upside from disruption and domination of knee OA market



6X

Go-2-Market Model can be shared upon NDA execution.



Expansion

15

Liposphere's technology shows potential in other lucrative markets





Cosmetics

Surface Coating (contact lenses, catheters, implants)

Drug delivery (pharma)



Liposphere Ltd. Aarava 1, 6th Floor Givat-Shmuel 5400804 Israel

Office: +972 (0) 732113227 E-Mail: contact@lipo-sphere.com www.lipo-sphere.com




in Follow us

© by Liposphere Ltd. 2023



AqueousJoint technology

Liposphere's joint articulation compound



Formulations hold water in the most efficient way.

Water acts as the lubricating element.